Ikena Oncology (IKNA) to Release Quarterly Earnings on Tuesday

Ikena Oncology (NASDAQ:IKNA - Get Free Report) is anticipated to release its Q4 2024 earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.

Ikena Oncology (NASDAQ:IKNA - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. On average, analysts expect Ikena Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Ikena Oncology Stock Up 0.7 %

Shares of NASDAQ IKNA traded up $0.01 during trading on Friday, reaching $1.44. 72,039 shares of the stock were exchanged, compared to its average volume of 200,654. The company has a market capitalization of $69.49 million, a price-to-earnings ratio of -1.17 and a beta of 0.49. The business's 50-day moving average price is $1.49 and its 200 day moving average price is $1.62. Ikena Oncology has a twelve month low of $1.22 and a twelve month high of $1.94.

Analysts Set New Price Targets

A number of research firms have recently weighed in on IKNA. Wedbush reissued a "neutral" rating and set a $2.00 price target on shares of Ikena Oncology in a research report on Monday, December 23rd. HC Wainwright restated a "buy" rating and issued a $4.00 target price on shares of Ikena Oncology in a research note on Monday, November 11th.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.